SahmAdrangi is the chief investment officer of Kerrisdale Capital and has been actively involved in the development of the organization since it was established in 2009.He launched the company with under $1 million but it currently manages a whopping $150 million. Mr. SahmAdrangi penetrated the industry by bringing to light the rot in Chinese companies such as the China Biotics and China Marine Food Group and these companies were subjected to strict action from the Securities and Exchange Commission.
His company Kerrisdale Capital Management conducts research on the best investments and publishing their findings on its website and even on twitter. Kerrisdale’s research aims to correct the widely accepted misconception about companies’ fundamental business prospects. To keep up with latest trends Mr. Adrangi has focused the firms’ efforts on several specific sectors where they have developed superior understanding.
Focusing on Biotechnology has been one of their goals. They have published research on young companies such as Bavarian Nordic, Zafgen, and Unilife among a host of other companies. They are also focused in the mining sector which they believe is very attractive just as the telecommunication sector. Apart from the many research published, Mr. Adrangi has been actively involved as an activist in several investments.
Mr. Adrangi began his financial career in credit where he leveraged high yield loan debt at the Deutsche Bank. He attained a Bachelor of Arts in Economics from Yale University and has been invited as a key speaker at numerous conferences all over the country. He has also appeared in interviews on CNBC apart from being widely published. Kerrisdale Capital Management recently gathered around $100 million from interested investors willing to be on a single stock. They planned to use the money gained to short the stock of a soon-to-be unveiled public company. Kerrisdale currently manages about $500 million including the new money that they had raised from investing on the unknown company. Kerrisdale’s main hedge fund makes its money by betting both for and against company stocks and boasts a return of about 28% annually.